ArcticZymes Technologies ASA Logo

ArcticZymes Technologies ASA

AZT.OL

(1.5)
Stock Price

17,74 NOK

5.56% ROA

6.23% ROE

115.99x PER

Market Cap.

2.045.030.280,00 NOK

4.42% DER

0% Yield

15.74% NPM

ArcticZymes Technologies ASA Stock Analysis

ArcticZymes Technologies ASA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ArcticZymes Technologies ASA Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (4%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 ROE

ROE in an average range (5.94%) suggests satisfactory profitability and decent utilization of shareholders' equity.

4 ROA

The stock's ROA (5.56%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's elevated P/BV ratio (6.2x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-619) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

ArcticZymes Technologies ASA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ArcticZymes Technologies ASA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

ArcticZymes Technologies ASA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ArcticZymes Technologies ASA Revenue
Year Revenue Growth
2002 6.969.394
2003 72.325.195 90.36%
2004 147.202.272 50.87%
2005 70.041.000 -110.17%
2006 72.973.000 4.02%
2007 73.217.000 0.33%
2008 51.702.000 -41.61%
2009 24.075.000 -114.75%
2010 25.909.000 7.08%
2011 23.032.000 -12.49%
2012 21.475.000 -7.25%
2013 22.108.000 2.86%
2014 33.026.000 33.06%
2015 53.280.000 38.01%
2016 71.904.000 25.9%
2017 66.686.000 -7.82%
2018 66.769.000 0.12%
2019 77.247.000 13.56%
2020 93.449.000 17.34%
2021 127.970.000 26.98%
2022 136.971.000 6.57%
2023 124.604.000 -9.93%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ArcticZymes Technologies ASA Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 4.017.504 100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ArcticZymes Technologies ASA General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 0
2003 0 0%
2004 29.839.664 100%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 56.843.000 100%
2010 13.581.000 -318.55%
2011 5.532.000 -145.5%
2012 6.103.000 9.36%
2013 6.109.000 0.1%
2014 5.643.000 -8.26%
2015 6.747.000 16.36%
2016 8.596.000 21.51%
2017 8.660.000 0.74%
2018 7.384.000 -17.28%
2019 0 0%
2020 0 0%
2021 5.343.000 100%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ArcticZymes Technologies ASA EBITDA
Year EBITDA Growth
2002 -155.365
2003 -5.372.068 97.11%
2004 4.583.292 217.21%
2005 55.459.000 91.74%
2006 3.406.000 -1528.27%
2007 57.016.000 94.03%
2008 -87.922.000 164.85%
2009 -82.140.000 -7.04%
2010 -26.338.000 -211.87%
2011 -17.504.000 -50.47%
2012 -22.298.000 21.5%
2013 -21.823.000 -2.18%
2014 -22.010.000 0.85%
2015 -15.562.000 -41.43%
2016 -18.313.000 15.02%
2017 -22.130.000 17.25%
2018 -11.884.000 -86.22%
2019 -46.000 -25734.78%
2020 52.994.000 100.09%
2021 62.887.000 15.73%
2022 47.662.000 -31.94%
2023 29.048.000 -64.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ArcticZymes Technologies ASA Gross Profit
Year Gross Profit Growth
2002 5.563.077
2003 57.195.919 90.27%
2004 134.047.083 57.33%
2005 55.459.000 -141.7%
2006 57.765.000 3.99%
2007 57.016.000 -1.31%
2008 46.846.000 -21.71%
2009 22.374.000 -109.38%
2010 24.219.000 7.62%
2011 21.154.000 -14.49%
2012 19.697.000 -7.4%
2013 19.602.000 -0.48%
2014 21.987.000 10.85%
2015 37.077.000 40.7%
2016 45.168.000 17.91%
2017 44.759.000 -0.91%
2018 47.403.000 5.58%
2019 58.347.000 18.76%
2020 92.318.000 36.8%
2021 124.085.000 25.6%
2022 131.791.000 5.85%
2023 120.540.000 -9.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ArcticZymes Technologies ASA Net Profit
Year Net Profit Growth
2002 -642.528
2003 -9.836.514 93.47%
2004 -2.735.328 -259.61%
2005 -15.446.000 82.29%
2006 -26.654.000 42.05%
2007 -18.665.000 -42.8%
2008 -52.179.000 64.23%
2009 -99.372.000 47.49%
2010 -28.541.000 -248.17%
2011 -20.103.000 -41.97%
2012 -24.318.000 17.33%
2013 -22.889.000 -6.24%
2014 -21.992.000 -4.08%
2015 -17.344.000 -26.8%
2016 -20.480.000 15.31%
2017 -24.938.000 17.88%
2018 -13.989.000 -78.27%
2019 -7.183.000 -94.75%
2020 83.119.000 108.64%
2021 46.380.000 -79.21%
2022 32.860.000 -41.14%
2023 24.244.000 -35.54%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ArcticZymes Technologies ASA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 -1 0%
2004 0 0%
2005 -1 0%
2006 -1 100%
2007 -1 0%
2008 -2 100%
2009 -4 50%
2010 -1 -300%
2011 -1 0%
2012 -1 0%
2013 -1 0%
2014 -1 0%
2015 0 0%
2016 0 0%
2017 -1 0%
2018 0 0%
2019 0 0%
2020 2 100%
2021 1 0%
2022 1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ArcticZymes Technologies ASA Free Cashflow
Year Free Cashflow Growth
2002 -1.503.700
2003 -8.905.618 83.12%
2004 -4.387.900 -102.96%
2005 -8.468.000 48.18%
2006 -32.590.000 74.02%
2007 -866.000 -3663.28%
2008 -68.012.000 98.73%
2009 -90.254.000 24.64%
2010 -26.755.000 -237.34%
2011 -16.297.000 -64.17%
2012 -26.732.000 39.04%
2013 -19.012.000 -40.61%
2014 -23.125.000 17.79%
2015 -14.456.000 -59.97%
2016 -20.632.000 29.93%
2017 -27.107.000 23.89%
2018 -20.992.000 -29.13%
2019 2.865.000 832.71%
2020 45.016.000 93.64%
2021 63.372.000 28.97%
2022 45.662.000 -38.78%
2023 7.959.000 -473.72%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ArcticZymes Technologies ASA Operating Cashflow
Year Operating Cashflow Growth
2002 -189.579
2003 -5.101.063 96.28%
2004 -3.046.449 -67.44%
2005 -8.468.000 64.02%
2006 -32.590.000 74.02%
2007 0 0%
2008 -65.657.000 100%
2009 -89.000.000 26.23%
2010 -24.965.000 -256.5%
2011 -10.811.000 -130.92%
2012 -24.583.000 56.02%
2013 -17.385.000 -41.4%
2014 -21.200.000 18%
2015 -12.886.000 -64.52%
2016 -19.278.000 33.16%
2017 -22.056.000 12.6%
2018 -18.279.000 -20.66%
2019 3.965.000 561.01%
2020 46.928.000 91.55%
2021 74.970.000 37.4%
2022 58.094.000 -29.05%
2023 14.961.000 -288.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ArcticZymes Technologies ASA Capital Expenditure
Year Capital Expenditure Growth
2002 1.314.121
2003 3.804.555 65.46%
2004 1.341.451 -183.61%
2005 0 0%
2006 0 0%
2007 866.000 100%
2008 2.355.000 63.23%
2009 1.254.000 -87.8%
2010 1.790.000 29.94%
2011 5.486.000 67.37%
2012 2.149.000 -155.28%
2013 1.627.000 -32.08%
2014 1.925.000 15.48%
2015 1.570.000 -22.61%
2016 1.354.000 -15.95%
2017 5.051.000 73.19%
2018 2.713.000 -86.18%
2019 1.100.000 -146.64%
2020 1.912.000 42.47%
2021 11.598.000 83.51%
2022 12.432.000 6.71%
2023 7.002.000 -77.55%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ArcticZymes Technologies ASA Equity
Year Equity Growth
2002 67.228.499
2003 56.752.611 -18.46%
2004 49.184.278 -15.39%
2005 127.758.000 61.5%
2006 105.711.000 -20.86%
2007 204.041.000 48.19%
2008 159.273.000 -28.11%
2009 61.154.000 -160.45%
2010 36.387.000 -68.07%
2011 44.164.000 17.61%
2012 20.727.000 -113.07%
2013 41.684.000 50.28%
2014 98.430.000 57.65%
2015 86.261.000 -14.11%
2016 67.508.000 -27.78%
2017 44.098.000 -53.09%
2018 53.898.000 18.18%
2019 46.477.000 -15.97%
2020 196.331.000 76.33%
2021 244.844.000 19.81%
2022 284.736.000 14.01%
2023 305.478.000 6.79%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ArcticZymes Technologies ASA Assets
Year Assets Growth
2002 7.634.713
2003 65.485.741 88.34%
2004 58.579.483 -11.79%
2005 140.593.000 58.33%
2006 123.746.000 -13.61%
2007 219.538.000 43.63%
2008 187.766.000 -16.92%
2009 92.201.000 -103.65%
2010 68.977.000 -33.67%
2011 56.443.000 -22.21%
2012 32.237.000 -75.09%
2013 53.780.000 40.06%
2014 111.130.000 51.61%
2015 101.072.000 -9.95%
2016 85.834.000 -17.75%
2017 61.683.000 -39.15%
2018 68.014.000 9.31%
2019 77.608.000 12.36%
2020 221.912.000 65.03%
2021 284.111.000 21.89%
2022 319.037.000 10.95%
2023 334.745.000 4.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ArcticZymes Technologies ASA Liabilities
Year Liabilities Growth
2002 -59.593.786
2003 8.733.130 782.39%
2004 9.395.205 7.05%
2005 12.835.000 26.8%
2006 18.035.000 28.83%
2007 15.497.000 -16.38%
2008 28.493.000 45.61%
2009 31.047.000 8.23%
2010 32.590.000 4.73%
2011 10.611.000 -207.13%
2012 10.328.000 -2.74%
2013 11.256.000 8.24%
2014 12.263.000 8.21%
2015 14.322.000 14.38%
2016 17.746.000 19.29%
2017 16.870.000 -5.19%
2018 14.116.000 -19.51%
2019 31.131.000 54.66%
2020 25.581.000 -21.7%
2021 39.267.000 34.85%
2022 34.301.000 -14.48%
2023 29.267.000 -17.2%

ArcticZymes Technologies ASA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.34
Net Income per Share
0.35
Price to Earning Ratio
115.99x
Price To Sales Ratio
17.29x
POCF Ratio
71.89
PFCF Ratio
263.09
Price to Book Ratio
6.65
EV to Sales
15.31
EV Over EBITDA
65.5
EV to Operating CashFlow
64.15
EV to FreeCashFlow
233.09
Earnings Yield
0.01
FreeCashFlow Yield
0
Market Cap
2,05 Bil.
Enterprise Value
1,81 Bil.
Graham Number
6.87
Graham NetNet
4.44

Income Statement Metrics

Net Income per Share
0.35
Income Quality
1.22
ROE
0.06
Return On Assets
0.06
Return On Capital Employed
0.05
Net Income per EBT
0.75
EBT Per Ebit
1.57
Ebit per Revenue
0.13
Effective Tax Rate
0.25

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.81
Operating Profit Margin
0.13
Pretax Profit Margin
0.21
Net Profit Margin
0.16

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.56
Free CashFlow per Share
0.15
Capex to Operating CashFlow
-0.72
Capex to Revenue
-0.17
Capex to Depreciation
-3.3
Return on Invested Capital
0.05
Return on Tangible Assets
0.06
Days Sales Outstanding
0
Days Payables Outstanding
366.68
Days of Inventory on Hand
964.44
Receivables Turnover
0
Payables Turnover
1
Inventory Turnover
0.38
Capex per Share
-0.41

Balance Sheet

Cash per Share
4,89
Book Value per Share
6,05
Tangible Book Value per Share
6.05
Shareholders Equity per Share
6.05
Interest Debt per Share
0.33
Debt to Equity
0.04
Debt to Assets
0.04
Net Debt to EBITDA
-8.43
Current Ratio
14.08
Tangible Asset Value
0,29 Bil.
Net Current Asset Value
0,25 Bil.
Invested Capital
0.04
Working Capital
0,26 Bil.
Intangibles to Total Assets
0.06
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
12760500
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ArcticZymes Technologies ASA Dividends
Year Dividends Growth

ArcticZymes Technologies ASA Profile

About ArcticZymes Technologies ASA

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, In vitro diagnostics, and biomanufacturing. It offers salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; shrimp alkaline phosphatase and derived kits for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; double-strand specific DNases and derived kits for the removal of double stranded DNA; polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining DNA /RNA fragments. It operates in Norway, Germany, Lithuania, Italy, other countries in Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was incorporated in 1990 and is headquartered in Tromsø, Norway.

CEO
Mr. Michael Benjamin Akoh
Employee
60
Address
Sykehusveien 23
Tromsø, 9294

ArcticZymes Technologies ASA Executives & BODs

ArcticZymes Technologies ASA Executives & BODs
# Name Age
1 Dr. Marie Ann Roskrow BSc. (Hons), MBBS (Hons), Ph.D.
Executive Chairman
70
2 Mr. Dirk Hahneiser
Vice President of Business Development & Marketing
70
3 Mr. Michael Benjamin Akoh
Chief Executive Officer
70
4 Dr. Jeremy Gillespie
Vice President of Corporate Development
70
5 Mr. Borge Sorvoll
Chief Financial Officer
70
6 Dr. Marit Sjo Lorentzen
Vice President of Operations
70

ArcticZymes Technologies ASA Competitors

Carasent ASA Logo
Carasent ASA

CARA.OL

(2.0)
BerGenBio ASA Logo
BerGenBio ASA

BGBIO.OL

(1.8)
Photocure ASA Logo
Photocure ASA

PHO.OL

(0.5)
Kitron ASA Logo
Kitron ASA

KIT.OL

(1.8)
VOW ASA Logo
VOW ASA

VOW.OL

(1.8)